The class action, filed in the U.S. District Court for the Northern District of California under the caption Velanki v. Hims & Hers Health, Inc., centers on claims that the company failed to disclose that it shared sensitive consumer health information with third-party advertising platforms, including Meta and Snap. Furthermore, the complaint alleges that Hims & Hers charged customers for prescriptions immediately upon submission of intake forms, despite claims that users would first consult with medical providers to determine appropriate treatments.
In section Releases
Investors Face November Deadline in Hims & Hers Securities Lawsuit
Investors who purchased Hims & Hers Health securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek lead plaintiff status in a pending securities fraud class action. The litigation follows allegations that the company misled shareholders regarding its privacy practices and billing procedures.
Regulatory scrutiny intensified on July 29, 2026, when the Federal Trade Commission initiated a lawsuit against the firm, citing deceptive privacy practices. Following the disclosure, Hims & Hers stock fell 14.73%, or $4.32 per share, closing at $25.00. Kessler Topaz Meltzer & Check, LLP, which is advising investors on recovery options, notes that affected shareholders may seek to act as lead plaintiffs to represent the class in the ongoing litigation.
Comments (0)
No comments yet. Be the first!